# Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma

> **NCT04291885** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Melanoma and Skin Cancer Trials Limited** · enrollment: 122 (actual)

## Conditions studied

- Merkel Cell Carcinoma
- Merkel Cell Carcinoma, Stage I
- Merkel Cell Carcinoma, Stage II
- Merkel Cell Carcinoma, Stage III
- Neuroendocrine Tumors
- Carcinoma Neuroendocrine Skin

## Interventions

- **DRUG:** Avelumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04291885
- **Lead sponsor:** Melanoma and Skin Cancer Trials Limited
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-26
- **Primary completion:** 2027-04-01
- **Final completion:** 2030-04-30
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04291885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04291885, "Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04291885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*